Clifford Chacha Mwita

Clifford Chacha Mwita

Auto-generated profile, based on publicly available information

Clifford Chacha Mwita

Afya Research Africa Nairobi Kenya

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Journal of Neurosciences in Rural Practice
Verified
Journal Article
Open access
CMClifford C. Mwita
Clifford C. Mwita
DKDuncan Kajia
Duncan Kajia
SGSamson Gwer
Samson Gwer
AEAnthony Etyang
Anthony Etyang
CNCharles Newton
Charles Newton
Background: Stroke is the second leading cause of death globally. Computerized tomography is used to distinguish between ischemic and hemorrhagic subtypes, but it is expensive and unavailable in low and middle income countries. Clinical stroke scores are proposed to differentiate between stroke subtypes but their reliability is unknown. Materials and Methods: We searched online databases for studies written in English and identified articles using predefined criteria. We considered studies in which the Siriraj, Guy’s Hospital, Besson and Greek stroke scores were compared to computerized tomography as the reference standard. We calculated the pooled sensitivity and specificity of the clinical stroke scores using a bivariate mixed effects binomial regression model. Results: In meta-analysis, sensitivity and specificity for the Siriraj stroke score, were 0.69 (95% CI 0.62-0.75) and 0.83 (95% CI 0.75-0.88) for ischemic stroke and 0.65 (95% CI 0.56-0.73) and 0.88 (95% CI 0.83-0.91) for hemorrhagic stroke. For the Guy’s hospital stroke score overall sensitivity and specificity were 0.70 (95% CI 0.53-0.83) and 0.79 (95% CI 0.68-0.87) for ischemic stroke and 0.54 (95% CI 0.42-0.66) and 0.89 (95% CI 0.83-0.94) for hemorrhagic stroke. Conclusions: Clinical stroke scores are not accurate enough for use in clinical or epidemiological settings. Computerized tomography is recommended for differentiating stroke subtypes. Larger studies using different patient populations are required for validation of clinical stroke scores.

2 June 2017 in Wellcome Open Research
Verified
Journal Article
Open access
PDF file
MBMary A. Bitta
Mary A. Bitta
SKSymon M. Kariuki
Symon M. Kariuki
CMClifford Mwita
Clifford Mwita
SGSamson Gwer
Samson Gwer
LMLeah Mwai
Leah Mwai
CNCharles Newton
Charles Newton
Background:Antimalarial drugs affect the central nervous system, but it is difficult to differentiate the effect of these drugs from that of the malaria illness. We conducted a systematic review to determine the association between anti-malarial drugs and mental and neurological impairment in humans. Methods:We systematically searched online databases, including Medline/PubMed, PsychoInfo, and Embase, for articles published up to 14th July 2016. Pooled prevalence, heterogeneity and factors associated with prevalence of mental and neurological manifestations were determined using meta-analytic techniques. Results:Of the 2,349 records identified in the initial search, 51 human studies met the eligibility criteria. The median pooled prevalence range of mental and neurological manifestations associated with antimalarial drugs ranged from 0.7% (dapsone) to 48.3% (minocycline) across all studies, while it ranged from 0.6% (pyrimethamine) to 42.7% (amodiaquine) during treatment of acute malaria, and 0.7% (primaquine/dapsone) to 55.0% (sulfadoxine) during prophylaxis. Pooled prevalence of mental and neurological manifestations across all studies was associated with an increased number of antimalarial drugs (prevalence ratio= 5.51 (95%CI, 1.05-29.04); P=0.045) in a meta-regression analysis. Headaches (15%) and dizziness (14%) were the most common mental and neurological manifestations across all studies. Of individual antimalarial drugs still on the market, mental and neurological manifestations were most common with the use of sulphadoxine (55%) for prophylaxis studies and amodiaquine (42.7%) for acute malaria studies. Mefloquine affected more domains of mental and neurological manifestations than any other antimalarial drug. Conclusions:Antimalarial drugs, particularly those used for prophylaxis, may be associated with mental and neurological manifestations, and the number of antimalarial drugs taken determines the association. Mental and neurological manifestations should be assessed following the use of antimalarial drugs.

1 January 2016 in Journal of Neurosciences in Rural Practice
Verified
Journal Article
Open access
PDF file
CMClifford Chacha Mwita
Clifford Chacha Mwita
JMJohnstone Muthoka
Johnstone Muthoka
SMStephen Maina
Stephen Maina
PMPhillip Mulingwa
Phillip Mulingwa
SGSamson Gwer
Samson Gwer
Background: Traumatic brain injury (TBI) is a major cause of death and disability worldwide and is mostly attributed to road traffic accidents in resource-poor areas. However, access to neurosurgical care is poor in these settings and patients in need of neurosurgical procedures are often managed by general practitioners or surgeons. Materials and Methods: A retrospective clinical audit of the initial management of patients with TBI in Thika Level 5 Hospital (TL5H), a Tertiary Hospital in Central Kenya. Seventeen audit criteria divided into five clinical domains were identified and patient case notes reviewed for compliance with each criterion. Data were analyzed separately for those below 13 years owing to differences in response to brain trauma in those below this age. Results: Overall, there was poor compliance with audit criteria in both groups. Among those below 13 years of age, only 3 out of 17 criteria achieved compliance and 4 out of 17 criteria achieved compliance for those above 13 years of age. Assessment for the need for a cervical radiograph (7.1% and 8.8% compliance) and administration of oxygen (21.4% and 20.6% compliance) had the worst performance in both groups. Conclusion: Poor compliance to audit criteria indicates the low quality of care for patients with TBI in TL5H. Quality improvement strategies with follow-up audits are needed to improve care. There is a need to develop and enforce evidence-based protocols and guidelines for use in the management of patients with TBI in sub-Saharan Africa.

1 July 2018 in Journal of Neurosciences in Rural Practice
Verified
Journal Article
Open access
PDF file
CMClifford C. Mwita
Clifford C. Mwita
FKFlorentius Koech
Florentius Koech
TSTitus Sisenda
Titus Sisenda
KPKirtika Patel
Kirtika Patel
BMBenson Macharia
Benson Macharia
DRDevendra Rahangdale
Devendra Rahangdale
Background: Astrocytomas are primary central nervous system tumors arising from astrocytes and accounting for up to 37.8% of all brain tumors seen in hospital-based studies from Africa. Despite being common, their patterns and short-term outcomes remain poorly studied in Kenya. Materials and Methods: A prospective, descriptive study involving consecutive patients with a histological diagnosis of astrocytoma seen in three hospitals located in Eldoret, Kenya. Clinicopathologic characteristics and outcomes were recorded and patients followed up for 12 weeks. Results: Thirty-one patients were recruited over a 1-year period. Majority of them were female (51.6%). Headache (83.9%) and focal neurological deficits (64.5%) were the most common presenting features. Among patients with high-grade tumors, mean duration of illness was 106.03 ± 162.16 days, median functional status was Karnofsky performance status (KPS) score 50, mean tumor size was 110.22 ± 46.16 cm3, and median magnetic resonance imaging (MRI) score was 17. Among patients with low-grade astrocytomas, mean duration of illness was 213.03 ± 344.93 days, median functional status was KPS score 40, mean tumor size was 53.49 ± 54.96 cm3 and median MRI score was 9. Glioblastoma multiforme (GBM) (71%) and diffuse astrocytoma (22.6%) were the predominant histological subtypes. The median Ki-67 proliferative index was 6% for pilocytic astrocytoma, 1.6% for diffuse astrocytoma, and 60% for GBM. Systemic and regional surgical complications occurred in 6.5% and 38.7% of patients, respectively. In-hospital mortality was 19.4% and increased to 25.8% at 12 weeks. The KPS score at discharge was 50 and improved to 60 at 12 weeks. Only 9.7% of patients had acceptable functional status at 12 weeks follow-up. Conclusions: In this locality, headache, focal neurological deficits, and reduced functional status are the most common presenting features of astrocytomas while GBM is the most common histological subtype. Tumors are highly proliferative and in the short-term, both surgical and functional outcome are suboptimal.

1 January 2012 in Annals of Neurosciences
Verified
Journal Article
Open access
CMClifford Mwita
Clifford Mwita
LMLeah Mwai
Leah Mwai
CNCharles Newton
Charles Newton
Quinine has anti-epileptic properties in animals. However, in humans this has not been systematically investigated. To examine the available research evidence on the effects of quinine on seizures in adults or children. We searched online databases for published and unpublished studies in any language from January 1966 to March 2011. We considered randomized controlled trials (RCTs) evaluating the use of quinine in comparison to other drugs in humans with malaria or other conditions, and that reported the prevalence of seizures. Random effects meta-analysis was used to pool effect estimates in order to determine the effect of quinine on the prevalence of seizures. We identified six randomized controlled trials on severe malaria. Quinine was compared to the artemisinin derivatives in all trials. A total of 8,244 patients were included. In the meta-analysis, there was no significant effect of quinine on the prevalence of seizures when compared to the artemisinin derivatives (Odds ratio (OR) =0.90, 95% Confidence Interval (95%CI) =0.63-1.30). There was significant heterogeneity (I(2)=66%, Chi-square=17.44, p=0.008). Subgroup analysis showed that quinine significantly reduced seizures when compared to artemether (OR = 0.66, 95%CI = 0.49-0.88) but when compared to artesunate, prevalence of seizures increased significantly (OR = 1.24, 95%CI = 1.05-1.47). There is no sufficient evidence to conclude that quinine has any antiepileptic properties in humans.

1 June 2013 in JBI Evidence Implementation
Verified
Journal Article
Closed access
CMClifford Chacha Mwita
Clifford Chacha Mwita
WAWalter Akello
Walter Akello
GSGloria Sisenda
Gloria Sisenda
EOEvans Ogoti
Evans Ogoti
DTDavid Tivey
David Tivey
DMDavid Mbogo
David Mbogo